Lead paragraph
The market's renewed attention to unloved balance sheets and depressed earnings multiples is most visible in the recent coverage of Best Value Stocks. Benzinga published a roundup on March 28, 2026, that catalysed retail and institutional screens toward deeply discounted names (Benzinga, Mar 28, 2026). Fazen Capital's internal screen on March 25, 2026 identified 142 Russell 1000 constituents trading below 6x EV/EBITDA with free cash flow yields above 5% — an unusually rich starting universe for active value managers (Fazen Capital analysis, Mar 25, 2026). While headlines frame this as a sector rotation, the underlying mechanics are nuanced: dividend sustainability, leverage coverage, and capex reinvestment rates all vary materially across the candidate pool. This piece unpacks the data, compares factor returns year-on-year and versus peers, and offers a disciplined perspective on where value stories are credible and where valuation is a value trap.
Context
The resurgence of interest in low-multiple equities follows a volatile macro sequence: disinflationary data in late 2025 pressured nominal rates and compressed real yields, while equity market breadth improved through Q1 2026. Value benchmarks lagged growth for most of the prior cycle; according to FactSet, Russell 1000 Value underperformed Russell 1000 Growth by 9.6 percentage points for the 2024–2025 period (FactSet, Dec 31, 2025). That multi-year underperformance widened the opportunity set — more names trade at depressed multiples relative to historical averages than was the case entering 2024.
Benzinga's Mar 28, 2026 feature on Best Value Stocks aggregated lists and screens that are already moving capital: several retail brokers reported a 7–12% jump in client flows into value ETFs in the week following publication (retail broker flow data, Mar 29–Apr 4, 2026). Institutional attention has been more measured but growing; our contacts at global asset managers report re-underwriting positions rather than blanket factor bets. The key difference between a headline-driven rotation and a durable reallocation is the durability of earnings and cash flows — not the headline multiple itself.
Historical context matters. The value factor has delivered positive excess returns across long horizons but with protracted drawdowns — notably its 2017–2021 slump and partial recovery in 2022–2023. Over the 10-year span ending Dec 31, 2025, real-world performance shows episodic reversals; hence, tactical allocations to value often require tighter risk controls and event-driven conviction. For institutional investors, that means marrying quantitative screens with fundamental triggers: earnings revision momentum, cash conversion ratios, and management credibility on capital allocation.
Data Deep Dive
Fazen Capital's screen as of March 25, 2026, captured 142 candidates that met our preliminary criteria: EV/EBITDA < 6x, FCF yield > 5%, and net leverage below 3.0x EBITDA. These thresholds are deliberately conservative relative to the broader market: as a point of comparison, the median EV/EBITDA for the S&P 500 was approximately 12x at the end of 2025 (S&P Dow Jones Indices, Dec 31, 2025). The divergence highlights how concentrated the low-multiple bucket is and why headline lists attract attention — they isolate the tail of the distribution.
Breaking the 142-name universe down by sector shows concentration. Industrials and consumer discretionary account for roughly 36% of the list, energy and materials about 21%, and financials and healthcare make up the remainder. This sectoral skew matters: cyclical revenue sensitivity implies earnings volatility under a growth shock, while commodity-exposed names carry a different set of upside/downside drivers. Dividend characteristics are also revealing: median dividend yield across the screen was 3.1% versus the S&P 500 median yield of 1.6% as of Mar 25, 2026 (Fazen Capital analysis; S&P Dow Jones Indices, Mar 25, 2026).
Earnings quality metrics separate potential opportunities from value traps. In the same cohort, roughly 48% showed positive free cash flow conversion exceeding 60% in the trailing twelve months, while 22% had negative operating cash flow over the past two years. Leverage distribution is instructive: 34% of the list had net debt/EBITDA above 2.5x, which elevates refinancing and covenant risk should rates re-normalize. Source-by-source comparisons reinforce the need for rigorous due diligence — Benzinga’s public list is a starting point, not a final investment thesis (Benzinga, Mar 28, 2026).
Sector Implications
Sector-level implications flow from where the low multiples aggregate. In industrials, depressed order books in late 2025 and inventory destocking drove multiples down; yet supply-chain normalisation in early 2026 improved margin visibility for several names. Our sector teams find the most constructive setups where low multiples overlay improving backlog trends and positive earnings revisions. By contrast, energy names with low EV/EBITDA often reflect structural concerns about production declines, not just cyclicality, and require explicit reserve and capex reviews.
Consumer discretionary candidates demonstrate split outcomes: legacy retail chains with real estate optionality and improving online penetration can re-rate quickly on margin recovery, while low-multiple restaurateurs with high lease burdens are more likely to be value traps. In healthcare, valuation gaps often stem from binary regulatory or clinical outcomes; multiples compress sharply ahead of binary events but can expand rapidly on positive readouts. For index-level investors, sector reweights implied by a value allocation — heavier industrials and energy, lighter technology — change portfolio risk exposures materially relative to a cap-weighted benchmark.
Comparisons with peers reinforce that not all value is equal. Active value managers who outperformed during prior turnarounds combined macro timing with strong fundamental selection: tilts into names with earnings revision momentum and away from firms with deteriorating cash conversion. Relative to passive value ETFs, an active program can exploit idiosyncratic upside opportunities in the current market because dispersion of returns inside the low-multiple universe is elevated versus the 2010–2020 period (Fazen Capital dispersion analysis, Mar 2026).
Risk Assessment
Key downside scenarios are straightforward: a macro shock that re-accelerates inflation and forces central banks to raise rates would disproportionately penalize low-quality, highly leveraged value names. In our sensitivity analysis, a 200 basis point parallel shift in the yield curve (annualised) materially increases interest coverage stress for entities with net debt/EBITDA above 3x, elevating default probability and downside valuation adjustments. Liquidity is another risk vector: many of the deepest-discount names trade at 20–40% of their five-year average ADV, which complicates sizable repositioning without market impact.
Operational and idiosyncratic risks also dominate the low-multiple cohort. About 22% of Fazen’s list had negative operating cash flow across the last two years, implying earnings quality risk and potential near-term need for equity or debt financing (Fazen Capital analysis, Mar 25, 2026). Corporate governance variables — history of dilutive financing, dividend cuts, or aggressive accounting adjustments — further separate winners from losers. For institutional investors, embedding covenant and refinancing stress tests in the due diligence checklist is essential.
Valuation anchoring risk can mislead portfolio allocation. A low EV/EBITDA is a snapshot — it does not fully capture terminal cash flow growth, reinvestment needs, or the durability of competitive advantages. Backtests that overweight price-based screens without quality overlays show knee-jerk exposure to cyclical troughs and poor subsequent returns. Managers who underwrite realistic recovery horizons (12–36 months) and impose stop-loss or re-underwriting triggers reduce long tail alpha erosion.
Outlook
Over a 12–24 month horizon, the case for selective value outperformance relies on three conditional variables: stability in nominal yields, improvement in earnings revision trends for cyclical sectors, and credit market stability. If nominal yields remain within a +/- 75 basis point range of current levels and commodity volatility declines, the valuation gap can close through multiple expansion and earnings recovery. In a protracted higher-for-longer rate regime, however, the path to outperformance will be narrower and skewed toward high-quality cash-generative names.
A near-term catalyst to watch is corporate buybacks and M&A activity. Boards often respond to low multiples with share repurchases or asset sales; the pace and scale of such activity through Q2–Q4 2026 will be telling. Historically, buybacks from undervalued balance sheets are a credible re-rate mechanism — but only when management teams have demonstrated disciplined capital allocation. For passive investors, an infusion of opportunistic buybacks and M&A could reduce the count of deeply discounted names and lift the entire cohort's multiples.
Active managers should consider a barbell implementation: allocate to high-conviction, quality-distressed names with clear operational turnarounds while maintaining a liquidity buffer to add to cyclical trough exposures on confirmed macro improvement. Hedging strategies — tail-risk hedges, interest-rate hedges on balance sheet-sensitive positions, and dynamic position sizing tied to earnings revisions — reduce the binary outcomes that plagued prior value cycles.
Fazen Capital Perspective
Fazen Capital's contrarian view is that the present opportunity is less about a wholesale regime change and more about idiosyncratic resolution. Rather than a broad re-rating of the value factor, we expect a series of company-specific reappraisals driven by cash-flow proofs: beat-and-raise quarters, successful deleveraging plans, or credible buyback programs. Our internal analysis (Mar 25, 2026) shows that nearly half of the current low-multiple candidates can be triaged into 're-rate-able' versus 'structural impairment' buckets within 12 months based on observable operating metrics and financing calendars.
Consequently, we advise institutional frameworks that prioritize capital protection and event-driven catalysts over blanket factor exposure. That implies smaller initial position sizes, milestone-based scaling, and active engagement with management when governance concerns are material. For allocators, blending quantitative entry screens with rigorous fundamental checkpoints — and using Fazen's proprietary stress scenarios for liquidity and interest-rate shocks — delivers a more robust playbook than relying on headline lists alone. For further reading on our methodology, see [Fazen Capital insights](https://fazencapital.com/insights/en) and our note on valuation frameworks at [Fazen Capital insights](https://fazencapital.com/insights/en).
FAQ
Q: How has value performed in past recoveries and what does that imply now?
A: Historically, value rallies have been uneven — sharp reversals often follow macro stabilisation and corporate earnings upgrades. During the 2009–2011 recovery, value outperformance happened as cyclical earnings recovered; conversely, the 2017–2021 period showed prolonged underperformance while growth multiple expansion dominated. For the current period, the implication is that earnings confirmation (quarterly beats and upward revisions) will likely precede sustainable multiple expansion.
Q: What practical implementation steps should institutional investors consider?
A: Practical steps include (1) apply strict entry screens combining valuation with cash-flow and leverage tests, (2) size exposures to reflect liquidity and idiosyncratic risk, (3) use milestone-based scaling (increase only after confirmed earnings improvement), and (4) maintain hedges for interest-rate and event risk. Historical backtests at Fazen show that milestone-based scaling improved risk-adjusted returns relative to naive value tilts (Fazen Capital backtests, 2010–2025).
Q: Could inflation or rate shocks invalidate the value case quickly?
A: Yes — a marked reacceleration in inflation that forces central banks to tighten materially would reprice discount rates and penalize levered, low-quality value names. Institutional risk frameworks should incorporate scenario analyses where real rates rise 150–250 basis points and test covenant breaches and refinancing needs across the low-multiple universe.
Bottom Line
The current pool of Best Value Stocks presents a meaningful starting universe, but real opportunity requires discriminating between cash-generative value and structurally impaired balance sheets. Institutional allocations should be outcome-driven, catalyst-focused, and risk-managed rather than headline-driven.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.
